ovarian cancer
Conditions
Interventions
Case series:Apatinib+Chemotherapy regimen
Sponsors
Zhejiang Cancer Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Female aged 18 to 70 years; 2. ECOG (Eastern Cooperative Oncology Group) 0~2; 3. Patients must have a life expectancy of at least 3 months; 4. Histologically or pathologically confirmed diagnosis of epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer and at the same time meeting the following criteria:histologically confirmed all epithelial cell tumors (excluding FNA, cytology and/or cell mass) of extrauterine Mulerian origin; FIGO-defined stage III, with gross (visible or palpable) residues Lesion stage or stage IV (FIGO stage will be evaluated after completing of initial pelvic and abdominal surgery); 5. Patients have not received chemotherapy or targeted therapy before(The neoadjuvant therapy is not included;the adjuvant treatment is defined as first-line treatment unless disease progression occurs within 6 months after adjuvant treatment); 6. Normal hemodynamic indices before the recruitment (including blood cell count and liver/kidney function ). For example: HB=90 g/L, ANC>1.5×10^9/L; PLT>100×10^9/L, TBIL<1.5 times of upper limit of normal reference value, ALT and AST<2.5 times of upper limit of normal reference value (Liver metastasis <5×ULN), and CR=1.25 ×ULN 7. Patients will take contraceptive measures for the duration of the treatments and 8 weeks after the last treatment; 8. Signed the Informed Consent Form.
Exclusion criteria
Exclusion criteria: 1. Borderline epithelial ovarian tumor (formerly known as low malignant potential tumor); 2. Non epithelial ovarian tumors (such as germ cell tumors and sex cord stromal tumors); 3. At the same time having primary endometrial carcinoma; 4. Previous history of primary endometrial cancer,but the following is excluded: (1) Stage I A cancer; (2) Invasion of superficial myometrium without invasion of lymphatic vessels; (3) Grade 3 or non poorly differentiated subtypes, including papillary serous fluid, clear cell or other FIGO3 grade lesions; 5. Patients with thyroid dysfunction and drug therapy can not control the maintenance of normal thyroid function; 6. Patients with active brain metastasis, cancerous meningitis and spinal cord compression; 7. Patients with poor blood pressure control (systolic blood pressure> 140 mmHg, diastolic blood pressure> 90 mmHg); 8. Patients with stage II myocardial ischemia or myocardial infarction, poor control of the arrhythmia (including QT interval male = 450 ms, female = 470 ms) and Grade III-IV cardiac insufficiency according to New York Heart Association (NYHA) criteria or echocardiography check: left ventricular ejection fraction (LVEF) 1.5 or prothrombin time (PT) > ULN + 4 seconds or APTT ULN > 1.5), with bleeding tendency or is treated with thrombolysis and anticoagulation; 10. A large number of serous effusion (including pleural effusion, ascites, pericardial effusion, etc.); 11. Patients who received major surgical operations or experienced severe traumatic injuries, bone fracture, or ulcers within 4 weeks before screening; 12. Have a variety of factors that affect oral medication (such as can not swallow, gastrointestinal resection, chronic diarrhea and intestinal obstruction, etc.); 13. Abdominal fistula, gastrointestinal perforation or abdominal abscess occurred within 6 months before screening; 14. Patients whose routine urine tests indicate that urine protein = ++ or verifies that the 24-h urine protein quantitation = 1.0 g; 15. Having a history of psychiatric abuse and can not quit or have mental disorders; 16. Benign ovarian and non-ovarian conditions, such as serous cystadenoma, should also be excluded in patients with other invasive malignant tumors in the past five years or at the same time; 17. Participating in other clinical trials at least 4 weeks before screening; 18. Pregnant and lactating women; Other situations that the researchers considered unsuitable for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS; | — |
Secondary
| Measure | Time frame |
|---|---|
| OS;ORR;DCR; | — |
Countries
China
Contacts
Public ContactTao Zhu
Zhejiang Cancer Hospital
Outcome results
None listed